ABSTRACT
the FDA's implementation of its premarket review authorities, we reviewed FDA actions on new product applications, publicly available data on industry applications to market new products, and related FDA guidance documents and public statements.
We conclude that the FDA has not implemented the premarket review process in a manner that prioritizes the protection of public health. In particular, the FDA has (1) prioritized the review Administration (FDA) with the authority to regulate tobacco products. As part of that authority, Congress provided that no new regulated tobacco products could enter the market without first undergoing review by the FDA. In a compromise negotiated with the tobacco industry, the law "grandfathers" tobacco products that were already on the market.
1 Products that were commercially available at the time the law was introduced and have not been changed in any meaningful way do not require FDA authorization to stay on the market. However, the law mandates that a manufacturer submit to FDA review before any new product, including new versions of previously available products, can be sold at retail. 2 One aim of the requirement is to address the tobacco industry's history of manipulating its products to maximize addictiveness and increase attractiveness to consumers and to prevent more harmful products from ever entering the market.
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In the six years since the enactment of the Tobacco Control Act, the FDA has failed to implement the premarket review process in a manner that maximizes the protection of public health. Instead, as explained in this Special Communication, the agency has misplaced its priorities, and thereby has undermined the potential public health benefits of tobacco regulation, in three distinct ways. First, rather than prioritize the removal of non-compliant products from the marketplace, the FDA has given precedence to the review of applications that allow for the introduction of new tobacco products. Second, the FDA has accommodated the tobacco industry's repeated submission of deficient premarket applications, rather than dismissing such flawed applications outright or allowing only reasonable amendments. Finally, even though industry marketing activities are widely publicized, the FDA has failed to prioritize the enforcement of premarket review against companies that have avoided the process entirely and introduced new or modified products to the market without 
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Background on the Tobacco Control Act's Premarket Review Provisions
The cutoff date for products that are "grandfathered"
and do not require FDA review is February 15,
2007.
1 Any new or modified product introduced after that date must be authorized by the FDA before it can be sold. This includes any entirely new brand or subbrand of a product, as well as any modification to a legally marketed product. 1 Whether the FDA will authorize a new product to be sold depends on the manufacturer's ability to demonstrate that it has satisfied the criteria for one of the regulatory pathways for new products (figure 1). Under the Premarket Tobacco Product Application (PMTA) pathway, the manufacturer must show that introduction of a new product would be "appropriate for the protection of the public health," taking into account "the risks and benefits to the population as a whole, including users and nonusers of the tobacco product." 9 In essence, this requires the applicant to show that, on balance, allowing the sale of the new product would likely reduce tobacco-related harms. The Substantial Equivalence (SE) pathway provides for less rigorous review if a manufacturer can show that its product is nearly the same as a predicate "grandfathered" product.
When this pathway is being used, the FDA's task is to determine whether the product is different from the 
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The FDA has also publicly confirmed that it is prioritizing Regular SE applications, explaining that this focus is driven by the fact that Regular SE applications represent products that are not currently on the market. 12, 14-17, 19, 23 There is no public health Misplaced Priorities / 7 up its review, steady action on Regular SE applications and action on a handful of Provisional SE applications
has not yet significantly reduced the backlog with the number of SE applications pending before the agency having remained above 3,500 since March 2011 (figure 3). 19 The Misplaced Priorities / 10 to act, this gambit enabled these products to stay on the market for more than four years. Misplaced Priorities / 11 by the tobacco companies leave no doubt that these products are "new products" that ought to be subject to premarket review. There is also no doubt that the FDA has not issued orders authorizing the marketing of these products (all such orders are made public by the agency). Yet there has been no indication that the FDA has taken any enforcement action related to the marketing of these products, and most of them are still available in retail stores. RJR discontinued Revo because the product did not meet the company's expectations and the manufacturer has also removed Camel White from the market without a public announcement, but the other products remain available. [44] [45] In addition to these widely publicized new product releases, smokeless tobacco product manufacturers are making significant modifications to their products, the types of modifications that must be cleared with the FDA prior to marketing. For example, between 2010 and 2011, Marlboro Snus introduced a larger "round tin," similar in appearance to conventional moist snuff. 46 The snus pouches in the "round tin"
packaging are larger and contain a higher moisture content than the previous version. 46, 47 These changes appear to play a significant role in the level of nicotine and tobacco-specific N-nitrosamines in these products, and therefore have substantial implications for public health. Misplaced Priorities / 12
Policy Recommendations and Conclusion
The FDA has significant opportunities to improve the premarket review process to better protect public health. The authors suggest the following steps for immediate, impactful changes:
1. The FDA should reverse its prioritization of Regular over Provisional SE applications.
Provisional SE products that are currently on the market have been given a free pass for more than four years, despite the fact that many of them likely do not meet the legal test for substantial equivalence. Misplaced Priorities / 13 Act clearly requires, the public health gains of a review process will be minimal. The agency has had six years to implement a regulatory system, yet is has failed to meet this basic prerequisite for effective regulation.
Instead, the FDA has set priorities that undermine its ability to protect the public.
Rather than prioritizing the review of Provisional SE products that have been allowed to remain on the market without any oversight, the FDA has facilitated the introduction of additional tobacco products.
Likewise, rather than guard the marketplace from illegal or otherwise unauthorized products, the FDA has wasted resources by giving significant leeway to tobacco companies to correct applications that are grossly incomplete if not deliberately deficient.
Significant reform is needed for the FDA to satisfy its obligation to protect public health. Despite the premarket review requirements, there is evidence that the tobacco industry is introducing new products that have not been authorized by the FDA and the agency has yet to take an action to stop or prevent this practice despite the fact that the industry's actions have been made public. 
